ArticleData in brief2020
Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data.
Article in Data in brief, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Protein C and S activities in COVID-19: A systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2024Pooled it
- Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021): From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care (SFAR).Anaesthesia, critical care & pain medicine · 2021Guideline
- Is lupus anticoagulant testing with dilute Russell's viper venom clotting times reliable in the presence of inflammation?Research and practice in thrombosis and haemostasis · 2024Article
- Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection.Microorganisms · 2024Article
- Dysregulation of Protein S in COVID-19.Best practice & research. Clinical haematology · 2022Review
- Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.Nucleic acid therapeutics · 2022Article
- Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins.Journal of clinical medicine · 2022Article
- Exploring the pathways of inflammation and coagulopathy in COVID-19: A narrative tour into a viral rabbit hole.International reviews of immunology · 2022Review
- Clinical use of thrombin generation assays.Journal of thrombosis and haemostasis : JTH · 2021Review
- MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity.Journal of personalized medicine · 2021Article
- Age-Associated Increase in Thrombogenicity and Its Correlation with von Willebrand Factor.Journal of clinical medicine · 2021Review
- Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction.TH open : companion journal to thrombosis and haemostasis · 2021Article
- Could Daily Monitoring of Fibrin Related Markers Help Suspect a Thrombotic Event in COVID-19 Patients? A Prospective Pilot Study.TH open : companion journal to thrombosis and haemostasis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This data article accompanies the manuscript entitled: "Prothrombotic Disturbances of hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study" submitted to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.